All AbMole products are for research use only, cannot be used for human consumption.
Avelumab is a whole monoclonal antibody of isotype IgG1 that binds to the programmed death-ligand 1 (PD-L1) and therefore inhibits binding to its receptor programmed cell death 1 (PD-1). Formation of a PD-1/PD-L1 receptor/ligand complex leads to inhibition of CD8+ T cells, and therefore inhibition of an immune reaction. Immunotherapy aims at ceasing this immune blockage by blocking those receptor ligand pairs. In the case of avelumab, the formation of PD-1/PDL1 ligand pairs is blocked and CD8+ T cell immune response should be increased. PD-1 itself has also been a target for immunotherapy. Therefore, avelumab belongs to the group of immune checkpoint blockade cancer therapies. By retaining a native Fc-region, avelumab is thought to engage the innate immune system and may induce antibody-dependent cell-mediated cytotoxicity (ADCC).
Avelumab recognizes murine PD-L1
Chem Eng J. 2024 Nov 10.
Bioengineering human heavy-chain nanoferritin for glioblastoma multiforme-specific delivery and efficient immunotherapy
Avelumab (MSB0010718C) purchased from AbMole
Chem. 2022 Aug 11;8(8):2179-2191.
Spatially Resolved Cell Tagging and Surfaceome Labeling via Targeted Photocatalytic Decaging
Avelumab (MSB0010718C) purchased from AbMole
Acta Pharm Sin B. 2022 Aug 18.
Anti-PD-L1 antibody enhances curative effect of cryoablation via antibody-dependent cell-mediated cytotoxicity mediating PD-L1highCD11b+ cells elimination in hepatocellular carcinoma
Avelumab (MSB0010718C) purchased from AbMole
| Molecular Weight | 143829.40 |
| Formula | C6374H9898N1694O2010S44 |
| CAS Number | 1537032-82-8 |
| Storage | -80°C for long term |
| Related PD-1/PD-L1 Products |
|---|
| Panaxadiol
Panaxadiol exists in ginseng root and has neuroprotective and anti-tumor functions. Panaxadiol inhibits the expression of programmed cell death ligand-1 (PD-L1) and tumor proliferation. |
| Fraxinellone
Fraxinellone was isolated from the root bark of the brassica family Dictamnus dasycarpus. Fraxinellone is a PD-L1 inhibitor that inhibits HIF-1α synthesis without affecting HIF-1α degradation. Fraxinellone has potential for cancer immunity by targeting PD-L1. |
| BMS202
Bms-202 is an effective non-peptide PD-1/PD-L complex inhibitor with IC50 of 18 nM and KD of 8 μM. Bms-202 directly binds to PD-L1 and blocks the human PD-1/PD-L interaction. Bms-202 has antitumor activity. |
| Sulfamethoxypyridazine
Sulfamethoxypyridazine is a long-acting sulfonamide for treatment of Dermatitis herpetiformis. |
| Nivolumab
Nivolumab (nabumab) is a fully humanized IgG4 monoclonal antibody against PD-1. It has immune checkpoint inhibitory activity and antitumor activity; MW: 143.597 KD.(for human-derived mice). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
